scholarly journals Sugammadex: A neuromuscular blockade agent encapsulator

2017 ◽  
Vol 5 (20) ◽  
pp. 44 ◽  
Author(s):  
Victoria Yepes Hurtado
Keyword(s):  
Neuromuscular Blockade ◽  
Current Literature ◽  
Neuromuscular Blocking ◽  
Muscle Relaxants ◽  
Neuromuscular Blocking Agents ◽  
New Class ◽  
Blocking Agents

Sugammadex sodium, a modified γ-cyclodextrin, represents a new class of drugs effectiveat reversing non-depolarizing muscle relaxants rocuronium and vecuronium. The cylindrical,basket-like structure encapsulates neuromuscular blocking agents which results in rapidreversal of paralysis within three minutes. The current literature was reviewed to analyze theclinical implications and considerations with its administration.

Sugammadex is changing the paradigm in neuromuscular blockade in patients with myotonic dystrophy

2019 ◽  
Vol 29 (10) ◽  
pp. 337-340 ◽  
Author(s):  
Joana Teixeira ◽  
Bernardo Matias ◽  
Irene Ferreira ◽  
Tiago Taleço ◽  
João S Duarte
Keyword(s):  
General Anaesthesia ◽  
Myotonic Dystrophy ◽  
Neuromuscular Blockade ◽  
Perioperative Complications ◽  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Myotonic Dystrophy Type 1 ◽  
Myotonic Dystrophy Type ◽  
Blocking Agents

Myotonic dystrophy type 1 is a rare neuromuscular disease that represents a challenge to anaesthetic management. Most of the literature does not recommend the usage of neuromuscular blocking agents, if general anaesthesia is needed in these patients. Depolarising neuromuscular blocking agents like suxamethonium are contraindicated, and there might be an increased sensitivity to non-depolarising agents like rocuronium with greater risk of postoperative residual neuromuscular blockade and consequent respiratory failure. Reversing neuromuscular blockade is also problematic as neostigmine can induce myotonic crisis, impairing normal ventilation. We discuss the use of sugammadex for neuromuscular blockade reversal, from a clinical case of a patient with myotonic dystrophy type 1 for laparoscopic cholecystectomy. The patient had a general anaesthesia with neuromuscular blockade with rocuronium. After the surgical procedure, neuromuscular blockade was safely reversed with sugammadex, guided by neuromuscular monitoring without any perioperative complications.

Myopathy in Status Asthmaticus: Relation to Neuromuscular Blockade and Corticosteroid Administration

1993 ◽  
Vol 8 (3) ◽  
pp. 144-152 ◽  
Author(s):  
Janet M. Shapiro ◽  
Rany Condos ◽  
Randolph P. Cole
Keyword(s):  
Mechanical Ventilation ◽  
Creatine Kinase ◽  
Neuromuscular Blockade ◽  
Muscle Weakness ◽  
Status Asthmaticus ◽  
Rare Complication ◽  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Corticosteroid Administration ◽  
Blocking Agents

Myopathy is a rare complication that arises during management of status asthmaticus that may be related to administration of corticosteroids and neuromuscular blocking agents. We present 4 patients with myopathy and a review of the 31 previously reported patients in the literature. All patients received corticosteroids, and 33 of the 35 patients received neuromuscular blocking agents. Muscle weakness was often diffuse and, in several patients, involved the muscles of respiration. Creatine kinase values ranged from normal to markedly elevated. Diagnosis was obtained by electromyogram and muscle biopsy in most patients. Resolution of the muscle weakness occurred over a period of days to months. Patients in whom myopathy developed required mechanical ventilation for longer periods than patients intubated for status asthmaticus without myopathy.

Sign in / Sign up

Export Citation Format

Share Document